Literature DB >> 15831913

Placenta growth factor expression is correlated with survival of patients with colorectal cancer.

S-C Wei1, P-N Tsao, S-C Yu, C-T Shun, J-J Tsai-Wu, C H H Wu, Y-N Su, F-J Hsieh, J-M Wong.   

Abstract

BACKGROUND: Overexpression of vascular endothelial growth factor (VEGF) correlates with vascularity, metastasis, and proliferation in colorectal cancer but the role of its homologue, placenta growth factor (PlGF), is unknown. The aim of this study was to evaluate expression and clinical implications of PlGF in colorectal cancer.
METHODS: We investigated 74 tumour/non-tumour pairs of colorectal cryosections. Clinical staging was based on the UICC-TNM classification. Expression levels of mRNA for PlGF and VEGF were analysed with quantitative real time reverse transcription-polymerase chain reaction. Proteins were analysed by immunohistochemical staining and enzyme linked immunoabsorbant assay. Analysis of the differences in PlGF and VEGF levels between tumour and non-tumour tissues in the same patient were performed by paired t test; differences between localised and advanced disease patients by the Mann-Whitney, chi(2), and Fisher's exact tests and survival curves by the Kaplan-Meier method.
RESULTS: Expression levels for both growth factors were significantly higher in tumour than in non-tumour tissues (p</=0.001). The ratio of PlGF expression in tumour to non-tumour in the advanced disease group was significantly higher than for the localised disease group (p = 0.009). Patients with more tumour PlGF mRNA had shorter survival (p = 0.028). The majority of PlGF was expressed in tumour cells.
CONCLUSIONS: Our results suggest that PlGF expression correlates with disease progression and patient survival and may be used as a prognostic indicator for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831913      PMCID: PMC1774482          DOI: 10.1136/gut.2004.050831

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.

Authors:  W L Monsky; D Fukumura; T Gohongi; M Ancukiewcz; H A Weich; V P Torchilin; F Yuan; R K Jain
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

2.  Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

Authors:  Jennifer LeCouter; Dirk R Moritz; Bing Li; Gail Lewis Phillips; Xiao Huan Liang; Hans-Peter Gerber; Kenneth J Hillan; Napoleone Ferrara
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

Review 3.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 4.  Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders.

Authors:  M Autiero; A Luttun; M Tjwa; P Carmeliet
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

Review 5.  Expression and function of placenta growth factor: implications for abnormal placentation.

Authors:  Donald S Torry; Debashree Mukherjea; Juan Arroyo; Ronald J Torry
Journal:  J Soc Gynecol Investig       Date:  2003-05

6.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

7.  Microsatellite instability and hMLH1 and hMSH2 gene expression in Taiwanese hereditary nonpolyposis colorectal cancer.

Authors:  Shu-Chen Wei; Chia-Tung Shun; Jyy-Jih Tsai-Wu; C H Hebert Wu; Jin-Chuan Sheu; Cheng-Yi Wang; Jau-Min Wong
Journal:  J Formos Med Assoc       Date:  2004-05       Impact factor: 3.282

8.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.

Authors:  Monica Autiero; Johannes Waltenberger; Didier Communi; Andrea Kranz; Lieve Moons; Diether Lambrechts; Jens Kroll; Stephane Plaisance; Maria De Mol; Françoise Bono; Stefanie Kliche; Guido Fellbrich; Kurt Ballmer-Hofer; Domenico Maglione; Ulrike Mayr-Beyrle; Mieke Dewerchin; Saskia Dombrowski; Danica Stanimirovic; Paul Van Hummelen; Christoph Dehio; Daniel J Hicklin; Graziella Persico; Jean-Marc Herbert; David Communi; Masabumi Shibuya; Désiré Collen; Edward M Conway; Peter Carmeliet
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

9.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Authors:  Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

Review 10.  Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?

Authors:  Aernout Luttun; Monica Autiero; Marc Tjwa; Peter Carmeliet
Journal:  Biochim Biophys Acta       Date:  2004-03-04
View more
  31 in total

1.  Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection.

Authors:  H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-24       Impact factor: 4.584

2.  VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma.

Authors:  Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

Review 3.  Role of placenta growth factor in cancer and inflammation.

Authors:  Ki Jo Kim; Chul Soo Cho; Wan Uk Kim
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

4.  Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Wafaey Gomaa; Abdelbaset Buhmeida; Yousif Qari; Mohammad Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Tumour Biol       Date:  2014-06-09

5.  Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.

Authors:  Kristin Schneider; Astrid Weyerbrock; Soroush Doostkam; Karl Plate; Marcia Regina Machein
Journal:  J Neurooncol       Date:  2014-11-05       Impact factor: 4.130

Review 6.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Authors:  Jochen G Schneider; Sarah R Amend; Katherine N Weilbaecher
Journal:  Bone       Date:  2010-09-17       Impact factor: 4.398

7.  Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.

Authors:  Nibal Zaghloul; Sonia L Hernandez; Jae-O Bae; Jianzhong Huang; Jason C Fisher; Alice Lee; Angela Kadenhe-Chiweshe; Jessica J Kandel; Darrell J Yamashiro
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

Review 8.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

9.  Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.

Authors:  Xiabin Lan; Wei Sun; Ping Zhang; Liang He; Wenwu Dong; Zhihong Wang; Siming Liu; Hao Zhang
Journal:  Tumour Biol       Date:  2015-11-26

Review 10.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.